Assertio Holdings, Inc. (ASRT) Latest Filing Signal
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for Assertio Holdings, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, Assertio Holdings, Inc.'s filing signal
turned negative.
earningsVibe SuperAnalyst™ Verdict:
TURNED NEGATIVE
Signal Performance — Stock Price Since Filing
30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Continuing Negative
GEMINI
Continuing Negative
CLAUDE
Turned Negative
CHATGPT
Continuing Negative
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does Assertio Holdings, Inc. actually do?
Answer:
Assertio Holdings, Inc. is a pharmaceutical company focused on marketing products primarily within the oncology market, building its portfolio through acquisitions and licensing. Its lead product is ROLVEDON, a long-acting G-CSF analog for adult patients receiving anti-cancer drugs. The company also markets Sympazan, SPRIX, and INDOCIN, having divested Assertio Therapeutics in May 2025. Assertio relies on contract manufacturers for its products and operates solely within the U.S. market. In 2025, net product sales were $117.1 million, a slight decrease from $120.8 million in 2024, with ROLVEDON contributing $68.2 million.
Question:
What are Assertio Holdings, Inc.'s revenue drivers?
Answer:
Assertio's revenue is primarily driven by net product sales of its marketed pharmaceutical products, with ROLVEDON being the lead product. Royalty revenue from a licensing agreement for CAMBIA in Canada also contributes to overall revenue.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required